a-c PSMA ligands composed of a glutamine-urea-lysine PSMA-binding... | Download Scientific Diagram
Prof.Dr.LEVENT KABASAKAL | Ac-225-PSMA for Castration Resistant Metastatic Prostate Cancer
Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC | European Journal of Nuclear Medicine and Molecular Imaging
Lu-177 PSMA therapy vs Ac-225 PSMA therapy
Development of Novel 111In/225Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics | Journal of Medicinal Chemistry
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Advances in targeted alpha therapy for prostate cancer - ScienceDirect
A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... | Download Scientific Diagram
Synthesis of 225Ac-PSMA-617 for Preclinical Use | Bentham Science
Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. | Semantic Scholar
![Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00722/article_deploy/html/images/pharmaceutics-13-00722-g002.png "Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis")
Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
![Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy [Abstract]](https://www.thno.org/v11/p4050/toc.jpg "Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy [Abstract]")
Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy [Abstract]
Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer | RadioGraphics
²²⁵Ac-PSMA-617 and ²²⁵Ac-PSMA-TO-1 mouse overall survival. A... | Download Scientific Diagram
PSMAtreatment - What is actinium PSMA - PSMA Forum
Cancers | Free Full-Text | PSMA Theranostics: Science and Practice
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Ac-225 PSMA therapy
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients - Oncidium Foundation
![Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram](https://www.researchgate.net/publication/351584466/figure/fig1/AS:1024889205047296@1621364036254/Structural-formula-of-225-AcAc-PSMA-I-T-with-DOTAGA-as-a-chelator-Structural.png "Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram")
Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram
Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer - Oncidium Foundation
Cureus | A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer | Article
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F1.large.jpg "Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine")
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram
Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F6.large.jpg "Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine")
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy - ScienceDirect
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
